Pterostilbene protects against doxorubicin-induced cardiotoxicity in canines via a gut microbiota–6AN–NOX2 axis

Read full text Summarise with VIRAT
Authors: Yanan Zhang, Yuelei Chen, Xiaoxia Huang, Wei Gao, Kidong Eom, Jing Dong, Lin Li
Cited by: 0
References: 34

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Doxorubicin (DOX) is a powerful chemotherapeutic agent, but its clinical use is restricted by cumulative and irreversible cardiotoxicity. Intestinal dysbiosis has been linked to DOX-induced cardiac injury, yet the underlying mechanisms and therapeutic targets remain elusive. This study aimed to investigate whether pterostilbene (PTE), a natural prebiotic plant extract, alleviates DOX cardiotoxicity by regulating gut microbiota and their metabolites. Eighteen beagles were randomized into control, DOX (30 mg/m² weekly for 7 weeks), and PTE (50 mg/kg daily for 9 weeks) + DOX groups. Fecal microbiota transplantation (FMT) from canine donors to microbiota-depleted rats, 16S rRNA sequencing, metabolome analysis, and in vitro H9C2 cell experiments were conducted. Main outcomes included survival rate, cardiac function parameters, cardiac injury biomarkers, microbial diversity, and oxidative stress-related indicators. In beagles receiving cumulative DOX (30 mg/m 2 weekly for 7 weeks), PTE cotreatment (50 mg/kg daily for 9 weeks) significantly improved survival (83.3% vs. 50.0%, n=6/group) and attenuated myocardial injury, evidenced by reduced plasma CK and LDH activities (both p

Fields of Study & Subjects

Chemotherapy-induced cardiotoxicity and mitigation Gut microbiota and health Chemotherapy-induced organ toxicity mitigation

Publication details

Journal / source
Pathology - Research and Practice
Volume
282
Pages
156454–156454
Publication date
23 March 2026
Language
EN